[1] Mantovani A, Dalbeni A.Treatments for NAFLD: state of art[J]. Int J Mol Sci, 2021, 22(5): 2350. doi: 10.3390/ijms22052350. [2] Huang D Q, El-Serag H B, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. [3] Day C P, James O F.Steatohepatitis: a tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845. [4] Buzzetti E, Pinzani M, Tsochatzis E A.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65: 1038-1048. [5] Borrelli A, Bonelli P, Tuccillo F M, et al.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: current and innovative therapeutic approaches[J]. Redox Biol, 2018, 15: 467-479. [6] Tripathi A, Debelius J, Brenner D A, et al.The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411. [7] 卢素芳, 郑鹏程, 刘盼盼, 等. 青砖茶研究进展[J]. 茶叶学报, 2018, 59(3): 162-167. Lu S F, Zheng P C, Liu P P, et al.Research progress on Qingzhuan tea[J]. Acta Tea Sinica, 2018, 59(3): 162-167. [8] 张伟. 青砖茶对实验大鼠的减肥和调节血脂作用及其机制研究[D]. 武汉: 华中农业大学, 2009. Zhang W.Studies on anti-obesity, blood lipid regulation effects and mechanisms of dark brick tea on rats [D]. Wuhan: Huazhong Agricultural University, 2009. [9] 何建刚, 李世刚, 肖长义, 等. 青砖茶的抗氧化作用研究[J]. 农技服务, 2016, 33(3): 94-95. He J G, Li S G, Xiao C Y, et al.Research on antioxidant effect of Qingzhuan tea[J]. Agricultural Technology Service, 2016, 33(3): 94-95. [10] 陈玉琼, 张伟, 倪德江, 等. 湖北青砖茶辅助降血脂作用及其抗氧化效果[J]. 茶叶科学, 2010, 30(2): 124-128. Chen Y Q, Zhang W, Ni D J, et al.Study on the hypolipidemic effect and antioxidative activity of Hubei Qingzhuan tea[J]. Journal of Tea Science, 2010, 30(2): 124-128. [11] 刘云涛, 何建刚, 肖长义, 等. 湖北长盛川青砖茶对2型糖尿病合并血脂异常患者胰岛素抵抗、血脂的影响[J]. 中国老年学杂志, 2019, 39(6): 1317-1320. Liu Y T, He J G, Xiao C Y, et al.Effects of Hubei Changshengchuan green brick tea on insulin resistance and blood lipid in type 2 diabetes patients with dyslipidemia[J]. Chinese Journal of Gerontology, 2019, 39(6): 1317-1320. [12] 王蝶, 黄建安, 叶小燕, 等. 茯砖茶减肥作用研究[J]. 茶叶科学, 2012, 32(1): 81-86. Wang D, Huang J A, Ye X Y, et al.The anti-obesity effects of Fuzhuan brick tea on high-fat-diet induced obesity in rats[J]. Journal of Tea Science, 2012, 32(1): 81-86. [13] 赵伟, 孙国志. 不同种实验动物间用药量换算[J]. 畜牧兽医科技信息, 2010(5): 52-53. Zhao W, Sun G Z.Conversion of dosage between different kinds of experimental animals[J]. Chinese Journal of Animal Husbandry and Veterinary Medicine, 2010(5): 52-53. [14] 余婕, 闫梦真, 陈桂婷, 等. 青砖茶水提物对HepG2细胞脂肪变性的干预作用[J]. 三峡大学学报(自然科学版), 2020, 42(2): 107-112. Yu J, Yan M Z, Chen G T, et al.Intervention effect of water extract of green brick tea on steatosis of HepG2 cells[J]. Journal of China Three Gorges University (Natural Sciences), 2020, 42(2): 107-112. [15] Pierantonelli I, Svegliati-Baroni G.Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH[J]. Transplantation, 2019, 103(1): e1-e13. [16] Safari Z, Gérard P.The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)[J]. Cell Mol Life Sci, 2019, 76(8): 1541-1558. [17] Fan Y, Pedersen O.Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol, 2021, 19(1): 55-71. [18] Suk K T, Kim D J.Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(3): 193-204. [19] Milosevic I, Vujovic A, Barac A, et al.Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature[J]. Int J Mol Sci, 2019, 20(2): 395. doi: 10.3390/ijms20020395. [20] Zhu L, Baker S S, Gill C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57(2): 601-609. [21] Lee N Y, Shin M J, Youn G S, et al.Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis[J]. Clin Mol Hepatol, 2021, 27(1): 110-124. [22] Bashiardes S, Shapiro H, Rozin S, et al.Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5(9): 782-794. [23] Kolodziejczyk A A, Zheng D, Shibolet O, et al.The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med, 2019, 11(2): e9302. doi: 10.15252/emmm.201809302. [24] Leung C, Rivera L, Furness J B, et al.The role of the gut microbiota in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(7): 412-425. |